NCT03573102

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Effect of SGLT2 Inhibitor on Proteinuria in Diabetic Patients

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Nahla H Tohami · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co transporter 2 inhibitor , a new antihyperglycemic drug , on proteinuria and to compare its effect with the effect of classic antiproteinuric drugs as angiotensin converting enzyme inhibitor , aspirin and statins.

Detailed description

Diabetic nephropathy involves progressive stages including glomerular hyperfilteration , microalbuminuria , overt proteinuria and a decline in glomerular filteration rate leading to end stage renal disease. Despite all the available interventions available for diabetic patients including tight glycemic control , and blood pressure control , using angiotensin converting enzyme inhibitors, angiotensin II receptor antagonist renal disease remains prevalent and progress in these patients. The newer therapy of diabetes is the use of sodium glucose cotransporter 2 inhibitor as it has the potential of renoprotection in patients with diabetic nephropathy just as ACEI and ARBS to reduce glomerular hyperfilteration .This action may reduce albuminuria.

Conditions

• Diabetic Nephropathies

Interventions

Type	Name	Description
DRUG	SGLT2 inhibitor	SGLT2 inhibitor 10 mg/day
DRUG	ACE inhibitor	ACE inhibitor once daily

Timeline

• Start date: 2018-06-20
• Primary completion: 2020-06-01
• Completion: 2020-07-01
• First posted: 2018-06-29
• Last updated: 2020-04-21

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study